Xenon Pharmaceuticals has paused psychiatric trials of azetukalner due to adverse psychosis events, despite its advancement towards FDA review for treating focal seizures. Analysts remain optimistic about the drug's potential $2 billion market opportunity in epilepsy.
As Xenon Pharmaceuticals announced that azetukalner has reached the FDA for focal seizures, the company also disclosed the emergence of psychosis adverse events in psychiatric trials of the drug, triggering a temporary pause.
Original title: “Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity”